



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2016

---

**Enlarging Red Blood Cell Distribution Width During Hospitalization  
Identifies a Very High-Risk Subset of Acutely Decompensated Heart Failure  
Patients and Adds Valuable Prognostic Information on Top of  
Hemoconcentration**

Ferreira, João Pedro ; Girerd, Nicolas ; Arrigo, Mattia ; Medeiros, Pedro Bettencourt ; Ricardo, Miguel Bento ; Almeida, Tiago ; Rola, Alexandre ; Tolpannen, Heli ; Laribi, Said ; Gayat, Etienne ; Mebazaa, Alexandre ; Mueller, Christian ; Zannad, Faiez ; Rossignol, Patrick ; Aragão, Irene

DOI: <https://doi.org/10.1097/MD.0000000000003307>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-134362>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:

Ferreira, João Pedro; Girerd, Nicolas; Arrigo, Mattia; Medeiros, Pedro Bettencourt; Ricardo, Miguel Bento; Almeida, Tiago; Rola, Alexandre; Tolpannen, Heli; Laribi, Said; Gayat, Etienne; Mebazaa, Alexandre; Mueller, Christian; Zannad, Faiez; Rossignol, Patrick; Aragão, Irene (2016). Enlarging Red Blood Cell Distribution Width During Hospitalization Identifies a Very High-Risk Subset of Acutely Decompensated Heart Failure Patients and Adds Valuable Prognostic Information on Top of Hemoconcentration. *Medicine*, 95(14):e3307.

DOI: <https://doi.org/10.1097/MD.0000000000003307>

# Enlarging Red Blood Cell Distribution Width During Hospitalization Identifies a Very High-Risk Subset of Acutely Decompensated Heart Failure Patients and Adds Valuable Prognostic Information on Top of Hemoconcentration

João Pedro Ferreira, MD, PhD, Nicolas Girerd, MD, PhD, Mattia Arrigo, MD, Pedro Bettencourt Medeiros, MD, Miguel Bento Ricardo, MD, Tiago Almeida, MD, Alexandre Rola, MD, Heli Tolppanen, MD, Said Laribi, MD, PhD, Etienne Gayat, MD, PhD, Alexandre Mebazaa, MD, PhD, Christian Mueller, MD, PhD, Faiez Zannad, MD, PhD, Patrick Rossignol, MD, PhD, and Irene Aragão, MD

**Abstract:** Red blood cell distribution width (RDW) may serve as an integrative marker of pathological processes that portend worse prognosis in heart failure (HF). The prognostic value of RDW variation ( $\Delta$ RDW) during hospitalization for acute heart failure (AHF) has yet to be studied.

We retrospectively analyzed 2 independent cohorts: Centro Hospitalar do Porto (derivation cohort) and Lariboisière hospital (validation cohort). In the derivation cohort a total of 170 patients (age  $76.2 \pm 10.3$  years) were included and in the validation cohort 332 patients were included (age  $76.4 \pm 12.2$  years). In the derivation cohort the primary composite outcome of HF admission and/or cardiovascular death occurred in 78 (45.9%) patients during the 180-day follow-up period.

Discharge RDW and  $\Delta$ RDW were both increased when hemoglobin levels were lower; peripheral edema was also associated with increased discharge RDW (all  $P < 0.05$ ). Discharge RDW value was significantly

associated with adverse events: RDW  $> 15\%$  at discharge was associated with a 2-fold increase in event rate, HR = 1.95 (1.05–3.62),  $P = 0.04$ , while a  $\Delta$ RDW  $> 0$  also had a strong association with outcome, HR = 2.47 (1.35–4.51),  $P = 0.003$ . The addition of both discharge RDW  $> 15\%$  and  $\Delta$ RDW  $> 0$  to hemoconcentration was associated with a significant improvement in the net reclassification index, NRI = 18.3 (4.3–43.7),  $P = 0.012$ . Overlapping results were found in the validation cohort.

As validated in 2 independent AHF cohorts, an in-hospital RDW enlargement and an elevated RDW at discharge are associated with increased rates of mid-term events. RDW variables improve the risk stratification of these patients on top of well-established prognostic markers.

(*Medicine* 95(14):e3307)

**Abbreviations:** ACM = all-cause mortality, ADHF = acutely decompensated heart failure, CVM = cardiovascular mortality, ER = emergency room, Hb = hemoglobin, HF = heart failure, HR = hazard ratio, IDI = integrated discrimination improvement, LVEF = left ventricular ejection fraction, NP = natriuretic peptide, NRI = net reclassification index, NT-pro BNP = N-terminal-pro brain natriuretic peptide, RDW = red blood cell distribution width.

Editor: Jacek Bil.

Received: November 3, 2015; revised: February 11, 2016; accepted: March 16, 2016.

From the INSERM, Centre d'Investigations Cliniques Plurithématique 1433, INSERMU1116, Université de Lorraine, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France (JPF, NG, FZ, PR); Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (JPF); INSERM UMR-S 942, APHP Lariboisière University Hospital, F-CRIN INI-CRCT, Paris, France (MA, AR, HT, SL, EG, AM); Internal Medicine Department, Centro Hospitalar do Porto, Porto, Portugal (PBM, MBR, TA); Department of Anesthesiology and Critical Care Medicine, Saint Louis Lariboisière University Hospital, Assistance Publique – Hôpitaux de Paris; Université Paris Diderot, Paris, France (EG, AM); Cardiovascular Research Institute Basel (CRIB), University Hospital, Basel, Switzerland (CM); and Department of Cardiology, University Hospital, Basel, Switzerland; Intensive Care Unit, Centro Hospitalar do Porto, Porto, Portugal (IA).

Correspondence: João Pedro Ferreira, Centre d'Investigations Cliniques-INSERM CHU de Nancy, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 Rue du Morvan, 54500 Vandœuvre lès Nancy, France (e-mail: j.ferreira@chu-nancy.fr).

NG has received Board Membership fees from Novartis. PR has received Board Membership fees from Novartis, Relypsa, and Steathpeptides. FZ has received fees for serving on the board of Boston Scientific; consulting fees from Novartis, Takeda, AstraZeneca, Boehringer Ingelheim, GE Healthcare, Relypsa, Servier, Boston Scientific, Bayer, Johnson & Johnson, and Resmed, as well as speaker's fees from Pfizer and AstraZeneca. FZ and PR are cofounders of CardioRenal diagnostics.

All remaining authors have no conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ISSN: 0025-7974

DOI: 10.1097/MD.0000000000003307

## INTRODUCTION

Red blood cell distribution width (RDW) is a measure of size variability in the red blood cell population (anisocytosis). Its value is obtained by dividing the standard deviation of erythrocyte volume by the mean corpuscular volume and multiplied by 100 to express the result as a percentage.<sup>1</sup> Disorders related to ineffective erythropoiesis or increased red blood cell destruction cause greater heterogeneity in erythrocyte size and consequently higher RDW.<sup>2,3</sup> Hence, it has been advocated that RDW may serve as an integrative measure of nutritional deficiencies (e.g., iron and folate), bone marrow dysfunction, and/or systemic inflammation, all of which are associated with worse outcomes in heart failure (HF) patients.<sup>2,4</sup> An elevated RDW has been associated with mortality in several settings, such as coronary artery disease, chronic HF, acute HF, stroke, pulmonary hypertension, peripheral artery disease, critically ill patients, and severe sepsis/septic shock.<sup>4–11</sup> This finding is of major interest since RDW is inexpensive and widely available as part of the routine complete blood count.

Most studies have investigated the association of the RDW value with outcome using a single baseline measurement (in

various cohorts); however, much less is known regarding the impact of the changes in RDW during hospitalization. In fact, RDW may be considered as a dynamic variable with rapid changes in acute disease states.<sup>10</sup>

Hemoconcentration (increase in hemoglobin and/or hematocrit during hospitalization) has also been studied as a possible target to assess decongestion in HF.<sup>12–18</sup>

To the best of our knowledge, no previous study has addressed the dynamic changes of RDW in acutely decompensated heart failure (ADHF). Furthermore, the relationship between evolving RDW and hemoconcentration during hospitalization has yet to be tested.

We hypothesize that an increased RDW from baseline to discharge can improve prognostic information in comparison to discharge RDW alone, while increased RDW without hemoconcentration may help to identify very high-risk ADHF patients.

## METHODS

### Studied Population, Emergency Room Description, and Oversight

We analyzed 2 independent cohorts:

- (1) Porto cohort (derivation cohort) – during a 3-year period (from January 2012 to December 2014), all patients with ADHF admitted to the emergency room (ER) of the tertiary university hospital *Centro Hospitalar do Porto* (CHP), Porto, Portugal, were retrospectively studied. This ER has moreover certain noteworthy particularities. The ER is situated within the Urgency Department under the supervision of the Intensive Care Unit. The ER is equipped with ventilators and invasive monitoring devices in order to receive unstable/severe patients. The patients described in this cohort were all admitted for ADHF/pulmonary edema with associated respiratory insufficiency ( $\text{PaO}_2/\text{FiO}_2 < 300$ )
- (2) Paris cohort (validation cohort) – during a 4-year period (from January 2011 to December 2014), all patients with dyspnea admitted to the urgency of the tertiary university hospital Lariboisière, Paris, France, were prospectively recorded in a uniform database, which was retrospectively used for this study purposes, in which we selected only those patients an ADHF diagnosis.

All authors designed the study. The 1st, 3rd, 4th, 5th, and 6th authors collected, recorded, and adjudicated the data. The 1st 2 authors performed the statistical analysis and wrote the 1st draft of the manuscript. All authors edited and approved the manuscript and assume full responsibility for the accuracy and completeness of the data and for the fidelity of this report to the study protocol.

### Criteria and Definitions

Patients with ADHF criteria were included. The diagnosis of ADHF was performed according to the European Society of Cardiology (ESC) criteria, defined as a rapid or gradual onset of signs and symptoms of worsening HF resulting in unplanned hospitalization (including new onset acute HF).<sup>19,20</sup> Associated elevated natriuretic peptides (NPs) were used to adjudicate hospitalization whenever possible (83.5% of cases in Porto cohort and 96.4% of cases in Paris cohort). An echocardiographic study was performed on all patients during the index hospitalization. Left ventricular ejection fraction (LVEF) was measured by Simpson biplane method. Patients with acute myocardial infarction, systolic blood pressure  $<90$  mmHg,




FIGURE 1. ADHF = acutely decompensated heart failure.

mechanical cardiac support, chronic dialysis, and severe sepsis were excluded in order to mitigate inclusion bias and obtain a uniform dataset of severe ADHF patients – Figure 1.

Patient cases were recorded in a uniform database based on the information collected from the clinical records/reports. The study included cases from both community and referral hospitals. Underlying diseases, precipitating factors, clinical presentation, most recent echocardiography findings, and analytical results (including hemoglobin, hematocrit, RDW, electrolytes, plasma creatinine and urea, and NPs) were recorded at admission (i.e., first available data) and discharge (i.e., the last available data). Blood analyses were performed using the Advia 2120 Hematology Analyzer (Siemens Healthcare Diagnostics, Deerfield, IL) in CHP laboratory and Cell-Dyn Sapphire Analyser (ABBOTT Diagnostics) in Lariboisière laboratories. The

RDW value is reported as a coefficient of variation (percentage) of red blood cell volume. The normal reference range for RDW in these hospital laboratories is 11.5% to 14.5% with intra- and interassay variation coefficients of 3.6% and 6.5%, respectively.

The patients and/or their families who had been lost from electronic registries were contacted in order to incorporate an accurate, unbiased prognostic information.

In Porto cohort we studied 2 end-points: a composite outcome of hospitalization for ADHF or cardiovascular mortality (CVM) – whichever occurred first; and all-cause mortality (ACM). In Paris cohort we studied ACM as primary end-point, since the diagnosis for subsequent hospitalizations was not adjudicated.

Hospital admission for ADHF was defined according to the most recent guidelines.<sup>21</sup> The follow-up period was 180 days starting from the hospital admission date.

The study was carried out in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee.

The study flowchart for Porto cohort is provided in Figure 1.

## Statistical Analysis

The results are expressed as mean  $\pm$  standard deviation (SD) if the continuous variables had a normal distribution or as median (percentile<sub>25–75</sub>) if the distribution was skewed. Normality assumption was verified by visual discretion. Categorical variables are expressed as absolute numbers (n) and proportions (%).

The delta ( $\Delta$ ) RDW was calculated as the difference between the last and first values divided by the first (last – first/first  $\times$  100) to account only for the actual difference between the 2 values.  $\Delta$ RDW  $\leq$  0 was considered as a decrease while  $\Delta$ RDW  $>$  0 was considered as an increase. The first and last RDW were also dichotomized by rounded the median value (15% in both cohorts). In Porto cohort, delta hemoglobin (Hb) was also calculated, with  $\Delta$ Hb  $>$  0 considered as a hemoconcentration, for example, an increase in hemoglobin from admission to discharge, and  $\Delta$ Hb  $\leq$  0 considered as no hemoconcentration, that is, a decrease or no increase in hemoglobin from admission to discharge. In Paris cohort,  $\Delta$ Hb was not calculated because discharge Hb values were not available in the dataset.

Population characteristics were compared using the independent sample *t*-test for normally distributed continuous variables, the Mann–Whitney *U*-test for skewed variables, and Chi-square tests for categorical variables.

Linear regression analyses were performed to assess the linear association between RDW and determinants of clinical, biochemical, therapeutic, and cardiovascular parameters. Candidate variables were chosen based on their a priori likelihood of being associated with RDW after which a backward selection was performed. Linearity and goodness of fit were verified. Binary logistic regression analyses were also performed to assess the associations of medications with dichotomic RDW.

The primary outcome was a composite of hospitalization for ADHF or CVM in Porto cohort and ACM in Paris cohort. Univariable time-to-event comparisons were made using the log rank test and univariable Cox proportional hazards models. Survival was estimated with the Kaplan–Meier method. Cox proportional-hazards models were used to obtain unadjusted and covariate adjusted hazard ratios (HRs). Proportional hazards assumptions were verified, with covariates used for adjusted HRs chosen from demographic, clinical, and laboratory variables that had been previously found to be clinically relevant. All continuous variables included in the model were verified for linearity.

The increased discriminative value associated with the “net reclassification improvement” (NRI) was assessed at 180 days.<sup>22,23</sup> This method assesses the ability of a new model to reclassify subjects with and without a clinical event during follow-up. The ability of the new model to reclassify is summarized by the NRI statistic. The continuous NRI method developed by Uno<sup>23</sup> and implemented in the survIDINRI package of the R software (The R Foundation for Statistical Computing) was used. The continuous NRI method does not require a prior definition of strata risk, thus considering the change in the estimation prediction as a continuous variable. The integrated discrimination improvement (IDI) was also calculated and assesses the difference between the integrated sensitivity gain and the integrated specificity loss due to the addition of the studied estimator to the prognostic model.

Statistical analyses were performed using SPSS 23 software (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.) and the R software (The R Foundation for Statistical Computing).

A *P* value  $<$  0.05 was considered statistically significant (including for interaction).

## RESULTS

### Patient Characteristics

In Porto cohort a total of 170 patients were included. In this cohort the mean  $\pm$  SD age was  $76.2 \pm 10.3$  years. Half of the patients were male, most had a history of hypertension history (87.1%), diabetes mellitus was present in 52.9% of the patients, and ischemic heart disease was the most frequent underlying cause for HF (56.5%). The mean LVEF was  $43.8 \pm 11.1\%$  – Table 1. The mean PaO<sub>2</sub>/FiO<sub>2</sub> ratio was  $165 \pm 86$ . At admission, the vast majority of patients (98.8%) had signs of pulmonary congestion as assessed by interstitial pulmonary edema on chest X-ray, 54.7% had pleural effusion and 58.2% peripheral edema. No significant differences between  $\Delta$ RDW groups were found with regard to clinical congestion markers at admission. However, at discharge, a trend for a higher proportion of patients with peripheral edema was found in the  $\Delta$ RDW  $>$  0 group (17.6 vs 31.5, *P* = 0.054). Patients with  $\Delta$ RDW  $>$  0 had lower sodium, albumin, hemoglobin, and hematocrit levels as well as higher N-terminal-pro brain natriuretic peptide (NT-pro BNP), both at admission and discharge (all *P*  $<$  0.05). A trend toward lower levels of serum iron during hospitalization was also found in patients with  $\Delta$ RDW  $>$  0 ( $54.9 \pm 32.4$  vs  $43.5 \pm 15.0$ , *P* = 0.082) – Table 1.

The composite outcome of hospital admission for worsening HF and/or CVM occurred in 78 (45.9%) patients, and 43 (25.3%) subjects died from any cause during the 180-day follow-up period – Table 1.

The baseline characteristics and events of Paris cohort are presented in the Supplementary Material Table 1, <http://links.lww.com/MD/A883>.

### Factors Associated With RDW in Linear and Logistic Regression Analysis

In Porto cohort higher admission and discharge RDW levels were associated with lower levels of hemoglobin, hematocrit, and transferrin saturation levels (all *P*  $<$  0.05). The presence of peripheral edema at discharge was also likely to be associated with increased RDW (*P*  $<$  0.05). The  $\Delta$ RDW was increased in association with a reduction in  $\Delta$ Hb (*P*  $<$  0.05) – Table 2.

**TABLE 1.** Characteristics of the Study Population Globally and According to RDW Changes

Variables	Total (n = 170)	$\Delta$ RDW $\leq 0$ (n = 103)	$\Delta$ RDW $> 0$ (n = 59)	P-Value	% Missing Values
<b>Demographics and history</b>					
Age, years	76.2 $\pm$ 10.3	75.0 $\pm$ 9.9	77.5 $\pm$ 10.58	0.150	0
Male sex – n, %	85 (50)	56 (54.4)	25 (43.1)	0.170	0
Hypertension – n, %	148 (87.1)	91 (88.2)	50 (86.3)	0.692	0
Diabetes mellitus – n, %	90 (52.9)	57 (55.3)	30 (51.7)	0.659	0
COPD – n, %	34 (20)	20 (21.7)	12 (24.0)	0.759	12.4
AFib – n, %	80 (47.1)	47 (45.6)	28 (48.3)	0.747	0
<b>Heart failure characterization</b>					
Basal NYHA class				0.571	0
I – n, %	14 (8.2)	10 (9.7)	4 (6.9)		
II – n, %	106 (62.4)	65 (63.1)	34 (58.6)		
III – n, %	50 (29.4)	28 (27.2)	20 (34.5)		
Ischemic etiology – n, %	96 (56.5)	57 (55.3)	34 (58.6)	0.687	0
LVEF, %	43.8 $\pm$ 11.1	42.7 $\pm$ 10.8	45.9 $\pm$ 11.3	0.079	0
LVEF $< 40\%$ – n, %	65 (38.2)	45 (43.7)	16 (27.6)	<b>0.043</b>	
Beta-blockers – n, %	100 (58.8)	63 (61.2)	32 (55.2)	0.458	5.3
ACEi/ARBs – n, %	119 (70)	73 (70.9)	41 (70.7)	0.980	0
MRAs – n, %	23 (13.5)	12 (11.7)	9 (15.5)	0.484	0
<b>Admission clinical assessment of congestion</b>					
Peripheral edema – n, %	99 (58.2)	56 (54.9)	38 (65.5)	0.190	0.6
Interstitial edema X-ray – n, %	168 (98.8)	101 (98.1)	58 (100)	0.286	0
Pleural effusion X-ray – n, (%)	93 (54.7)	58 (56.9)	30 (51.7)	0.530	0.6
PaO <sub>2</sub> /FiO <sub>2</sub> ratio	165 $\pm$ 86	155 $\pm$ 78	177 $\pm$ 92	0.116	0.6
<b>Admission biochemical data</b>					
Urea, mg/dL	71.5 $\pm$ 48.4	70.1 $\pm$ 52.9	69.2 $\pm$ 37.2	0.912	0
Creatinine, mg/dL	1.56 $\pm$ 1.17	1.54 $\pm$ 1.21	1.40 $\pm$ 0.64	0.428	0
eGFR, mL/min/1.73 m <sup>2</sup>	56.7 $\pm$ 32.0	56.7 $\pm$ 32.0	48.6 $\pm$ 28.3	0.543	1.7
Sodium, mmol/L	137.5 $\pm$ 5.1	138.6 $\pm$ 4.0	135.7 $\pm$ 6.4	<b>0.001</b>	0
Potassium, mmol/L	4.34 $\pm$ 0.82	4.28 $\pm$ 0.84	4.33 $\pm$ 0.71	0.745	0
Albumin, mg/dL*	3.6 $\pm$ 0.6	3.7 $\pm$ 0.5	3.4 $\pm$ 0.6	<b>0.001</b>	25.9
Total protein, mg/dL*	6.6 $\pm$ 0.9	6.7 $\pm$ 1.0	6.5 $\pm$ 0.8	0.358	26.5
NT-pro BNP/100, pg/mL	38.8 (15.5–79.0)	28.8 (12.0–67.2)	54.4 (27.0–97.0)	<b>0.001</b>	16.5
Hemoglobin, g/dL	12.5 $\pm$ 2.2	12.8 $\pm$ 2.4	12.0 $\pm$ 1.4	<b>0.024</b>	0.6
Hematocrit, %	38.7 $\pm$ 5.9	39.5 $\pm$ 6.2	37.3 $\pm$ 5.2	<b>0.024</b>	0.6
RDW, %	15.4 $\pm$ 2.7	15.6 $\pm$ 3.1	15.0 $\pm$ 1.6	0.105	0.6
RDW $> 15\%$ – n, %	69 (40.6)	41 (39.8)	23 (39.7)	0.985	
Serum iron, $\mu$ g/dL*	51.8 $\pm$ 29.7	54.9 $\pm$ 32.4	43.5 $\pm$ 15.0	0.082	65.9
Ferritin, ng/mL*	226 (107–453)	234 (139–465)	178 (94–414)	0.236	66.5
Transferrin saturation, %*	16 (11–21)	16 (11–21)	16 (11–20)	0.718	67.1
<b>Discharge clinical assessment of congestion</b>					
Peripheral edema – n, %	35 (20.6)	16 (17.6)	17 (31.5)	0.054	11.2
Interstitial edema X-ray – n, %	42 (24.7)	22 (34.9)	19 (40.4)	0.555	32.4
Pleural effusion – n, %	22 (12.9)	13 (14.1)	9 (14.3)	0.979	10.0
<b>Discharge biochemical data</b>					
Urea, mg/dL	70.9 $\pm$ 45.1	73.6 $\pm$ 47.4	66.5 $\pm$ 41.6	0.340	2.9
Creatinine, mg/dL	1.70 $\pm$ 4.49	1.93 $\pm$ 5.66	1.32 $\pm$ 0.83	0.417	3.5
eGFR, mL/min/1.73 m <sup>2</sup>	61.9 $\pm$ 31.1	61.6 $\pm$ 32.7	63.3 $\pm$ 28.9	0.748	1.0
Sodium, mmol/L	139.7 $\pm$ 4.3	139.6 $\pm$ 4.3	139.6 $\pm$ 4.2	0.959	2.4
Potassium, mmol/L	4.29 $\pm$ 0.59	4.30 $\pm$ 0.55	4.30 $\pm$ 0.67	0.969	2.4
NT-pro BNP/100, pg/mL	60.3 (9.8–49.3)	15.6 (8.5–41.9)	23.6 (8.5–41.5)	<b>0.021</b>	25.9
Hemoglobin, g/dL	11.9 $\pm$ 2.0	12.3 $\pm$ 2.0	11.3 $\pm$ 1.8	<b>0.003</b>	1.2
Hematocrit, %	36.8 $\pm$ 5.5	37.7 $\pm$ 5.7	35.5 $\pm$ 5.1	<b>0.015</b>	2.9
RDW, %	15.1 $\pm$ 2.1	14.6 $\pm$ 1.9	15.9 $\pm$ 2.2	<b>&lt;0.001</b>	4.7
RDW $> 15\%$ – n, %	58 (34.1)	26 (25.2)	32 (55.2)	<b>&lt;0.001</b>	
$\Delta$ RDW, %	–0.99 $\pm$ 9.14	–4.89 $\pm$ 7.93	5.95 $\pm$ 6.75	<b>&lt;0.001</b>	
<b>Length of stay and events</b>					
Length of stay, days	11 (7–15)	10 (7–15)	13 (9–20)	<b>0.010</b>	0
180-day ACM – n, %	43 (25.3)	17 (16.5)	23 (39.7)	<b>0.001</b>	0
180-day CVM – n, %	29 (17.1)	10 (9.7)	16 (27.6)	<b>0.003</b>	0
180-day composite outcome – n, %	78 (45.9)	36 (35.0)	37 (63.8)	<b>&lt;0.001</b>	0

eGFR was calculated by the modified diet and renal disease (MDRD) formula. Bold, significant value ( $P \leq 0.05$ ). Composite outcome, includes the first event of CVM or hospitalization for worsening heart failure.  $\Delta$ =adjusted delta (discharge – admission/admission  $\times$  100). ACEi/ARBs=angiotensin converting enzyme inhibitors/angiotensin receptor blockers, ACM=all-cause mortality, AFib=atrial fibrillation, COPD=chronic obstructive pulmonary disease, CVM=cardiovascular mortality, LVEF=left ventricular ejection fraction, MRA=mineralocorticoid receptor antagonist, n=number, NT-pro BNP=N-terminal pro brain natriuretic peptide, NYHA=New York Heart Association, RDW=red blood cell distribution width.

\*Any measure during hospitalization.



**TABLE 2.** Multiple Linear Regression Analysis of RDW at Admission, Discharge, and  $\Delta$ RDW

Admission RDW	Adjusted $R^2$	Beta	Intercept B (95% CI)	Sd. Error	P-Value
Overall model fit	0.22	—	—	2.92	<b>&lt;0.001</b>
Constant	—	—	19.34 (16.78 to 21.90)	1.29	<b>&lt;0.001</b>
Hemoglobin, g/dL	0.10	−0.32	−0.38 (−0.55 to −0.21)	0.09	<b>&lt;0.001</b>
Hematocrit, %*	0.04	−0.23	−0.10 (−0.17 to −0.04)	0.03	<b>0.003</b>
Transferrin saturation, %	0.08	−0.31	−0.09 (−0.17 to −0.02)	0.04	<b>&lt;0.001</b>
<b>Discharge RDW</b>					
Overall model fit	0.75	—	—	1.09	<b>&lt;0.001</b>
Constant	—	—	1.29 (−3.22 to 5.80)	2.23	<b>0.567</b>
Admission RDW, %	0.32	0.57	0.45 (0.35 to 0.55)	0.05	<b>&lt;0.001</b>
Hemoglobin, g/dL	0.17	−0.42	−0.44 (−0.59 to −0.29)	0.08	<b>&lt;0.001</b>
Hematocrit, %*	0.07	−0.28	−0.11 (−0.16 to −0.05)	0.03	<b>&lt;0.001</b>
Transferrin saturation, %	0.05	−0.25	−0.07 (−0.13 to 0.01)	0.03	<b>0.064</b>
Discharge peripheral edema, yes	0.02	0.17	0.84 (0.04 to 1.63)	0.40	<b>0.039</b>
<b><math>\Delta</math>RDW</b>					
Overall model fit	0.28	—	—	7.78	<b>&lt;0.001</b>
Constant	—	—	−23.94 (−31.13 to −16.75)	3.84	<b>&lt;0.001</b>
Admission RDW, %	0.13	0.37	−1.66 (−2.13 to −1.20)	0.24	<b>&lt;0.001</b>
$\Delta$ Hemoglobin	0.06	−0.25	−13.62 (−24.04 to −3.21)	5.27	<b>0.011</b>

Bivariate correlations were 1st assessed, after which the variables with significant correlations were entered in the linear regression model in which a backward selection was used. Only the final variables retained in the model are presented. In the admission RDW model, the following variables were tested: age, sex, atrial fibrillation (yes/no), LVEF, peripheral edema (yes/no), interstitial edema on chest X-ray (yes/no), pleural effusion on chest X-ray (yes/no), urea, creatinine, sodium, potassium, hemoglobin, hematocrit, albumin, total protein, iron, ferritin, transferrin saturation, and NT-pro BNP/100 (admission values were used unless stated otherwise). In the discharge RDW model, the following variables were tested: age, sex, atrial fibrillation (yes/no), LVEF, peripheral edema (yes/no), interstitial edema on chest X-ray (yes/no), pleural effusion on chest X-ray (yes/no), admission RDW, urea, creatinine, sodium, potassium, hemoglobin, hematocrit, albumin, total protein, iron, ferritin, transferrin saturation, and NT-pro BNP/100 (discharge values were used whenever available). In the  $\Delta$ RDW model, the following variables were tested: age, sex, atrial fibrillation (yes/no), LVEF, peripheral edema (yes/no), interstitial edema on chest X-ray (yes/no), pleural effusion on chest X-ray (yes/no), admission RDW, urea, creatinine, sodium, potassium, hemoglobin, hematocrit, albumin, total protein, iron, ferritin, transferrin saturation, and NT-pro BNP/100 (adjusted delta values were used whenever available). Bold, significant value ( $P \leq 0.05$ ).  $\Delta$  = adjusted delta (discharge–admission/admission). NT-pro BNP = N-terminal pro brain natriuretic peptide, RDW = red blood cell distribution width, Sd. Error = standard error.

\*Collinearity between hematocrit was found; however, hematocrit was forced in the final model to demonstrate that it also accounts for a significant part of the RDW value (both at admission and discharge), but to a lesser extent than hemoglobin.

In Porto cohort, the odds of having admission RDW >15% were increased by the presence of atrial fibrillation, and the odds of having RDW >15% at discharge were increased by higher RDW value at admission (both  $P < 0.05$ ). The odds of having  $\Delta$ RDW >0 were significantly increased in patients with peripheral edema at discharge – Table 3.

The factors associated with RDW values (both continuous and categorical) in Paris cohort are presented in the Supplementary Material Tables 2 and 3, <http://links.lww.com/MD/A883>.

In Porto cohort admission, discharge and  $\Delta$ RDW were negatively correlated with the corresponding Hb values (Pearson correlation = −0.32, −0.42, and −0.25, respectively, all  $P < 0.01$ ) – Figure 2.

### Association of RDW With Outcome

In Porto cohort, the RDW value (continuous and categorical) at admission was not significantly associated with the composite outcome of heart failure hospitalization or cardiovascular death. In contrast, discharge RDW value (continuous and categorical >>15%) was significantly associated with

outcome. The last median RDW value >15% was independently associated with composite outcome, even after stepwise adjustment for potential confounders (sex, age, LVEF, atrial fibrillation, the presence of peripheral edema, NT-pro BNP level, sodium, urea, and Hb), whereas the last RDW as continuous variable did not remain significantly associated after adjustment for the confounding variables included in model 3 (the presence of peripheral edema, NT-pro BNP level, sodium, urea, and Hb) – Table 4 and Figure 3. Importantly, a  $\Delta$ RDW >0 (i.e., an increase in the RDW value from admission to discharge) had a strong independent association with outcome (HR = 2.47 (1.35–4.51),  $P = 0.003$ , after adjustment for the variables included in model 3) – Table 4 and Figure 3. The strength of the association with the composite outcome was magnified when considering patients with both discharge RDW >15% and  $\Delta$ RDW >0 (HR = 3.40 (1.63–7.08),  $P = 0.001$ , after adjustment for the variables included in model 3) – Table 4 and Figure 3. Considering ACM as outcome in Porto cohort, the associations of discharge RDW (continuous), discharge RDW >15%,  $\Delta$ RDW >0, and discharge RDW >15% plus  $\Delta$ RDW >0 together, were also positive and independently significant –

**TABLE 3.** Multiple Logistic Regression Analysis of RDW ( $\leq 15$  vs  $>15\%$  at Admission and Discharge),  $\Delta$ RDW ( $\leq 0$  vs  $>0$ )

RDW $>15\%$ at Admission	OR (95% CI)	P-Value
Atrial fibrillation, yes	3.69 (1.89–7.19)	<b>&lt;0.001</b>
Hemoglobin, g/dL	0.80 (0.69–0.94)	<b>0.006</b>
RDW $>15\%$ at discharge		
Admission RDW, %	2.75 (1.87–4.04)	<b>&lt;0.001</b>
Hemoglobin, g/dL	0.72 (0.56–0.93)	<b>0.011</b>
$\Delta$ RDW $>0$		
Discharge peripheral edema, yes	2.84 (1.07–7.61)	<b>0.036</b>

A backward model was used and only the final variables retained in the model are presented. In the admission RDW model, the following variables were tested: age, sex, atrial fibrillation (yes/no), LVEF, peripheral edema (yes/no), interstitial edema on chest X-ray (yes/no), pleural effusion on chest X-ray (yes/no), urea, creatinine, sodium, potassium, hemoglobin, hematocrit, albumin, total protein, iron, ferritin, transferrin saturation, and NT-pro BNP/100 (admission values were used unless stated otherwise). In the discharge RDW model, the following variables were tested: age, sex, atrial fibrillation (yes/no), LVEF, peripheral edema (yes/no), interstitial edema on chest X-ray (yes/no), pleural effusion on chest X-ray (yes/no), admission RDW, urea, creatinine, sodium, potassium, hemoglobin, hematocrit, albumin, total protein, iron, ferritin, transferrin saturation, and NT-pro BNP/100 (discharge values were used whenever available). In the  $\Delta$ RDW model, the following variables were tested: age, sex, atrial fibrillation (yes/no), LVEF, peripheral edema (yes/no), interstitial edema on chest X-ray (yes/no), pleural effusion on chest X-ray (yes/no), admission and last RDW, urea, creatinine, sodium, potassium, hemoglobin, hematocrit, albumin, total protein, iron, ferritin, transferrin saturation, and NT-pro BNP/100 (adjusted delta values were used whenever available). Bold, significant value ( $P \leq 0.05$ ).  $\Delta$  = adjusted delta (discharge–admission/admission). NT-pro BNP = N-terminal pro brain natriuretic peptide, OR = odds ratio, RDW = red blood cell distribution width.

Supplementary Material Table 6, <http://links.lww.com/MD/A883>. Overlapping results were found in Paris cohort: the associations of discharge RDW (continuous), discharge RDW  $>15\%$ , increasing  $\Delta$ RDW,  $\Delta$ RDW  $>0$ , and discharge RDW  $>15\%$  plus  $\Delta$ RDW  $>0$  together, were also positive and independently associated with the outcome of ACM. Of notice,


in patients with both discharge RDW  $>15\%$  and  $\Delta$ RDW  $>0$  the association with outcome were particularly strong (HR = 3.82 (1.57–9.32),  $P = 0.003$ , after adjustment for the variables included in model 2) – Supplementary Material Table 4, <http://links.lww.com/MD/A883>.

### Association of $\Delta$ RDW and Hemoconcentration With Regard to Composite Outcome

In Porto cohort patients without hemoconcentration (defined by a decrease in Hb from admission to discharge or  $\Delta$ Hb  $\leq 0$ ) and  $\Delta$ RDW  $>0$ , the association with adverse events was very strong (HR = 4.98 [1.61–15.35],  $P = 0.005$ , after adjustment for the variables included in model 3) – Table 4 and Figure 3. Of note, no significant interactions were found between the studied RDW values and several independent variables (including Hb). Hemoconcentration was not measured in Paris cohort due to unavailability of discharge Hb in the dataset.

### Net Reclassification Indices

In Porto cohort, the increased discriminative value associated with the addition of RDW and hemoconcentration on top of the covariates age, LVEF, Hb, creatinine, and NT-pro BNP at admission was evaluated in order to predict the 180-day primary composite outcome using NRI. The addition of the last RDW  $>15\%$  and  $\Delta$ RDW  $>0$  in the survival model was associated with a significant improvement in reclassification (NRI = 23.1 [7.5–46.5],  $P = 0.013$  and IDI = 8.2 [2.2–18.0],  $P < 0.001$ ) – Table 5 and Figure 4. Of note, the addition of the last RDW  $>15\%$  and  $\Delta$ RDW  $>0$  on top of the aforementioned variables plus hemoconcentration was also associated with a significant improvement in reclassification (NRI = 18.3 [4.3–43.7],  $P = 0.012$  and IDI = 7.8 [1.2–17.1],  $P < 0.001$ ) – Table 5 and Figure 4. Discharge RDW  $>15\%$  and  $\Delta$ RDW  $>0$  alone also improved reclassification indices, whereas hemoconcentration alone did not – Table 5. In Porto cohort, the increased discriminative value associated with the addition of discharge RDW, RDW  $>15\%$  and  $\Delta$ RDW  $>0$  on top of a survival model including the covariates age, LVEF, Hb, creatinine, and NT-pro BNP at admission also significantly improved the net reclassification for 180-day ACM prediction (NRI for discharge RDW continuous = 34.7 (–2.0 to 50.0),  $P = 0.073$ ; NRI for discharge RDW  $>15\%$  = 35.6 (3.6–55.1),  $P = 0.040$ ; and NRI for  $\Delta$ RDW  $>0$  = 37.2 (6.0–55.4),  $P = 0.020$ ) – Supplementary Material Table 7, <http://links.lww.com/MD/A883>. Overlapping results were found in Paris cohort – Supplementary Material Table 5, <http://links.lww.com/MD/A883>.




**FIGURE 2.** RDW = red blood cell distribution width,  $\Delta$  = adjusted delta (discharge–admission/admission).

TABLE 4. Univariable and Multivariable Cox Proportional Hazards Models for 180-day Composite Outcome According to RDW Values

Variable	Univariable HR (95% CI)	P-Value	Model 1 HR (95% CI)	P-Value	Model 2 HR (95% CI)	P-Value	Model 3 HR (95% CI)	P-Value
RDW (%) at admission	1.05 (0.98–1.11)	0.182	1.05 (0.98–1.12)	0.166	1.06 (0.99–1.14)	0.087	1.01 (0.84–1.12)	0.987
RDW (%) at discharge	1.14 (1.04–1.25)	<b>0.005</b>	1.13 (1.03–1.25)	<b>0.010</b>	1.15 (1.04–1.28)	<b>0.005</b>	1.07 (0.93–1.22)	0.325
RDW ≤15% at admission	Reference		Reference		Reference		Reference	
RDW >15% at admission	1.28 (0.82–2.00)	0.288	1.21 (0.77–1.91)	0.416	1.28 (0.79–2.07)	0.312	1.29 (0.71–2.33)	0.410
RDW ≤15% at discharge	Reference		Reference		Reference		Reference	
RDW >15% at discharge	1.97 (1.24–3.13)	<b>0.004</b>	1.89 (1.17–3.04)	<b>0.009</b>	2.05 (1.26–3.33)	<b>0.004</b>	1.95 (1.05–3.62)	<b>0.036</b>
ΔRDW	1.02 (0.99–1.05)	0.120	1.02 (0.99–1.05)	0.197	1.02 (0.99–1.05)	0.251	1.04 (1.00–1.08)	<b>0.034</b>
ΔRDW ≤0	Reference		Reference		Reference		Reference	
ΔRDW >0	2.18 (1.37–3.45)	<b>0.001</b>	2.10 (1.32–3.56)	<b>0.002</b>	2.02 (1.26–3.25)	<b>0.004</b>	2.47 (1.35–4.51)	<b>0.003</b>
RDW discharge ≤15% and ΔRDW ≤0	Reference		Reference		Reference		Reference	
RDW discharge ≤15% and ΔRDW >0	2.26 (1.20–4.25)	<b>0.012</b>	2.20 (1.17–4.17)	<b>0.015</b>	1.98 (1.02–3.82)	<b>0.042</b>	1.55 (0.68–3.56)	0.301
RDW discharge >15% and ΔRDW ≤0	1.99 (0.99–3.97)	0.053	1.90 (0.94–3.84)	0.075	1.97 (0.97–4.00)	0.061	0.82 (0.25–2.68)	0.820
RDW discharge >15% and ΔRDW >0	2.96 (1.65–5.33)	<b>&lt;0.001</b>	2.87 (1.56–5.27)	<b>0.001</b>	2.94 (1.60–5.40)	<b>0.001</b>	3.40 (1.63–7.08)	<b>0.001</b>
ΔRDW ≤0 and Δhemoglobin >0	Reference		Reference		Reference		Reference	
ΔRDW ≤0 and Δhemoglobin ≤0	1.51 (0.71–3.23)	0.286	1.60 (0.75–3.45)	0.225	1.58 (0.73–3.39)	0.244	2.63 (0.83–8.38)	0.105
ΔRDW >0 and Δhemoglobin >0	1.92 (0.64–5.74)	0.241	1.91 (0.63–5.75)	0.251	1.85 (0.61–5.63)	0.278	6.14 (1.44–26.16)	0.091
ΔRDW >0 and Δhemoglobin ≤0	3.23 (1.54–6.78)	<b>0.002</b>	3.21 (1.53–6.74)	<b>0.002</b>	3.05 (1.44–6.47)	<b>0.004</b>	4.98 (1.61–15.35)	<b>0.005</b>

RDW discharge ≤15% and ΔRDW ≤0 (n = 77); RDW discharge ≤15% and ΔRDW >0 (n = 26); RDW discharge >15 and ΔRDW >0 (n = 32); ΔRDW ≤0 and Δhemoglobin >0 (n = 34); ΔRDW ≤0 and Δhemoglobin ≤0 (n = 68); ΔRDW >0 and Δhemoglobin >0 (n = 11); ΔRDW >0 and Δhemoglobin ≤0 (n = 47); Δhemoglobin >0 = hemoconcentration, that is, increase in hemoglobin from admission to discharge, and Δhemoglobin ≤0 = no hemoconcentration, that is, decrease or no increase in hemoglobin from admission to discharge. Model 1, adjusted for sex and age; Model 2, adjusted for sex, age, LVEF, and AFib; Model 3, adjusted for peripheral edema, NT-pro BNP, sodium, urea, and hemoglobin (all at discharge). No statistically significant interactions were found between the interest and explanatory variables. Bold, significant value ( $P \leq 0.05$ ). Δ = adjusted delta (discharge–admission/admission). AFib = atrial fibrillation, HR = hazard ratio, LVEF = left ventricular ejection fraction, NT-pro BNP = N-terminal pro brain natriuretic peptide, RDW = red blood cell distribution width.





**FIGURE 3.** Group 1: RDW discharge  $\leq 15\%$  and  $\Delta RDW \leq 0$ ; group 2: RDW discharge  $\leq 15\%$  and  $\Delta RDW > 0$ ; group 3: RDW discharge  $> 15\%$  and  $\Delta RDW \leq 0$ ; group 4: RDW discharge  $> 15\%$  and  $\Delta RDW > 0$ ; group 5:  $\Delta RDW \leq 0$  and  $\Delta Hemoglobin > 0$ ; group 6:  $\Delta RDW \leq 0$  and  $\Delta Hemoglobin \leq 0$ ; group 7:  $\Delta RDW > 0$  and  $\Delta Hemoglobin > 0$ ; and group 8:  $\Delta RDW > 0$  and  $\Delta Hemoglobin \leq 0$ . RDW = red blood cell distribution width,  $\Delta$  = adjusted delta (discharge–admission/admission).

**TABLE 5.** Net Reclassification Improvement and Integrated Discrimination Improvement for Predicting Composite Outcome at 180 days

Added Variable (s)	Baseline Set of Variables	NRI, %	P-Value	IDI, %	P-Value
Discharge RDW (continuous)	on top of age, LVEF, Hb, pCr, and NT-pro BNP	17.9 (−1.4 to 33.8)	0.080	3.6 (0.3 to 8.8)	<b>0.027</b>
Discharge RDW >15%		21.7 (0.1 to 37.1)	<b>0.047</b>	4.5 (0.1 to 13.3)	<b>0.020</b>
ΔRDW >0		29.6 (−0.1 to 44.1)	0.053	5.6 (−0.0 to 13.4)	<b>0.050</b>
Discharge RDW >15% and ΔRDW >0	on top of age, LVEF, Hb, pCr, NT-pro BNP, and hemoconcentration	23.1 (7.5 to 46.5)	<b>0.013</b>	8.2 (2.2 to 18.0)	<b>&lt;0.001</b>
ΔHemoglobin >0 (hemoconcentration)		8.7 (−9.0 to 25.7)	0.276	1.8 (−0.2 to 8.4)	0.106
Discharge RDW (continuous)		16.3 (−4.6 to 40.0)	0.105	3.3 (−4.6 to 40.0)	0.052
Discharge RDW >15%		24.7 (−1.2 to 40.1)	0.066	5.1 (0.0 to 13.7)	<b>0.040</b>
ΔRDW >0		30.0 (−1.5 to 43.3)	0.060	4.7 (0.1 to 12.2)	<b>0.033</b>
Discharge RDW >15% and ΔRDW >0		18.3 (4.3 to 43.7)	<b>0.012</b>	7.8 (1.2 to 17.1)	<b>&lt;0.001</b>

The prediction models include age in years (<77 vs ≥77), left ventricular ejection fraction in % (<45 vs ≥45), hemoglobin in g/dL (<12 vs ≥12), creatinine in mg/dL (<1.5 vs ≥1.5), NT-pro BNP in pg/mL (<3500 vs ≥3500) at admission and Δhemoglobin >0 (hemoconcentration). ΔHemoglobin >0 = hemoconcentration, that is, increase in hemoglobin from admission to discharge, and Δhemoglobin ≤0 = no hemoconcentration, that is, decrease or no increase in hemoglobin from admission to discharge. Bold, significant value ( $P \leq 0.05$ ). Δ = adjusted delta (discharge–admission/admission). Hb = hemoglobin, IDI = integrated discrimination improvement, LVEF = left ventricular ejection fraction, NRI = net reclassification improvement, NT-pro BNP = N-terminal pro brain natriuretic peptide, pCr = plasma creatinine, RDW = red blood cell distribution width.


DISCUSSION

The present study shows that an enlarging RDW from admission to discharge and elevated discharge RDW values were independently associated with mid-term adverse events over and above hemoconcentration (as measured by a change in Hb during hospitalization). In addition, discharge RDW >15% and ΔRDW >0, either alone or combined (especially the latter), improved the prognostic model that included several well-established prognostic variables plus hemoconcentration. Except for hemoconcentration, these results were validated in

2 independent cohorts, and provide highly useful, simple, pragmatic, and costless prognostic information with the potential to be used in daily clinical practice.

RDW as Prognostic Marker in Heart Failure and Its Incremental Prognostic Utility

The prognostic value of RDW in HF is well established in chronic HF. The CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program included 2679 symptomatic chronic HF patients from North



**FIGURE 4.** The prediction models include age in years (<77 vs ≥77), left ventricular ejection fraction in % (<45 vs ≥45), hemoglobin in g/dL (<12 vs ≥12), creatinine in mg/dL (<1.5 vs ≥1.5), NT-pro BNP in pg/mL (<3500 vs ≥3500) at admission, and Δhemoglobin >0 (hemoconcentration). ΔHemoglobin >0 = hemoconcentration, that is, increase in hemoglobin from admission to discharge, Δ = adjusted delta (discharge–admission/admission). Hb = hemoglobin, IDI = integrated discrimination improvement, LVEF = left ventricular ejection fraction, NRI = net reclassification improvement, NT-pro BNP = N-terminal pro brain natriuretic peptide, pCr = plasma creatinine, RDW = red blood cell distribution width.

America in an analysis of 36 routine laboratory tests and their association with mortality. Higher RDW showed the greatest association with mortality and was among the most powerful overall predictors, with only age and cardiomegaly showing a better independent association with outcome. This finding was then replicated in the Duke Databank, in which higher RDW was strongly associated with ACM.<sup>6</sup> In the ADHF setting the evidence is scarcer, nonetheless in 628 patients hospitalized for ADHF in Spain, a higher RDW at discharge (both continuous and categorical) was significantly associated with increased mortality independently of Hb value or anemia status. Additionally, RDW was also found to be associated with elevated troponin T, a marker of cardiomyocyte injury, and death in HF populations.<sup>24</sup> These studies used a single RDW value as prognostic predictor. To the best of our knowledge, the present study is the first to show that a rising RDW during hospitalization is independently associated with adverse events (hospitalization and/or CVM) at 180 days. The predictive value of rising RDW was also present in patients with discharge RDW below the median of 15%. Of particular note, when rising RDW and discharge RDW >15% were added to a prognostic model including well-established HF prognostic markers (age, LVEF, Hb, creatinine, NT-pro BNP, and hemoconcentration), the capacity of the model to reclassify patients with and without event was significantly improved. The incremental prognostic utility of this finding merits serious consideration given its simplicity, its readily availability to all clinicians, without additional discomfort to the patients, and without cost escalation. This finding is of utmost importance since current HF risk prediction models do not take into account how individual patient assessments occur in incremental steps and, furthermore, each additional diagnostic assessment may add additional costs, complexity, and potential morbidity.<sup>25</sup>

### RDW and Hemoconcentration

Ineffective decongestion is responsible for many ( $\approx 35\%$ ) early readmissions,<sup>26</sup> with a high burden both for the patient and the health-care system.<sup>27</sup> The lack of available data to help clinicians in decongestion strategies is worrisome and requires further investigation.<sup>28,29</sup> More recently, hemoconcentration has emerged as a possible target to assess decongestion in HF,<sup>12–18</sup> particularly when assessed both at admission and discharge, since early improvements in congestion that are not sustained through hospital stay are not likely to be associated with improved outcomes.<sup>30</sup> The difference between admission and discharge Hb is likely to be a good candidate to assess hemoconcentration.<sup>29</sup> Moreover, our study showed that RDW is inversely correlated with Hb and adds prognostic information in addition to hemoconcentration, again with simple routine blood count values. It is thus likely that RDW and Hb evolving in opposite directions (increasing RDW and decreasing Hb) during hospital stay portends a worse prognosis.

### Potential Mechanisms

A rising RDW implies a reduction in structurally normal hemoglobin molecules.<sup>3</sup> In our series, patients with  $\Delta\text{RDW} > 0$  were more likely to have more peripheral edema, lower sodium, albumin, Hb and hematocrit levels, and higher NT-pro BNP at discharge. A trend toward lower levels of serum iron during hospitalization was also found in patients with  $\Delta\text{RDW} > 0$ . All of these factors are associated with worse prognosis in HF.<sup>31,32</sup> The underlying mechanism to these associations has yet to be elucidated, although probably reflects a higher disease severity

incorporating several pathophysiological processes such as nutritional deficiencies, inflammatory state, and renal dysfunction.<sup>6,33</sup> In our study, RDW values are likely to be partially explained by hemoglobin/hematocrit (both admission and discharge RDW), transferrin saturation (discharge RDW), and by the presence of peripheral edema (discharge RDW). Nevertheless, a large proportion of variability in RDW cannot be explained by the several parameters tested herein, thus reinforcing the possibility that RDW serves as an integrative measure of several pathophysiological mechanisms such as anemia, nutritional deficiencies, and possibly congestion. Recent data have demonstrated that patients whose erythrocyte indices are evolving toward an iron deficient picture (i.e., rising RDW and falling mean corpuscular volume) have a higher risk of mortality, independently of their anemia status.<sup>34</sup> Nonetheless, these data do not provide a clear basis for the prognostic implication of a rising RDW during such a short period of time (median length of stay in our dataset = 11 days), such that any potential conclusive explanation at this point is merely speculative.

### Clinical Implications

Our data provide useful clinical information derived from routine blood count without additional discomfort to the patient or cost increase. The present findings show that an enlargement in RDW from admission to discharge is associated with mid-term adverse events, even more so if the patients exhibit RDW >15% at discharge or no hemoconcentration (defined by Hb at discharge – Hb at admission), thereby adding further prognostic value to well established prognostic markers independently of hemoconcentration. As a result, this simple measure should help to identify patients likely to benefit from individualized strategies, thereby enabling a closer follow-up and/or tailored therapeutic strategies. This additional information particularly relevant in patients with ADHF renders serial hemograms even more useful during and possibly after ADHF hospitalization, with both hemoconcentration and RDW changes being assessed in routine clinical practice hemograms.

### Limitations

Several limitations should be acknowledged in this study. First, this is a 2-center, retrospective study (information was prospectively recorded in the validation cohort) with potential bias with regard to patient selection and information recording, although the present data were monitored in both cohorts and are consistent with previous studies in other fields as referenced in the discussion. Thus, our findings are likely to be generalizable. RDW was necessarily prospectively measured within the routine blood count (low risk of measurement bias – at least as low as in routine practice), was available in all but few patients (low risk of selection bias), and the used end-points were objective and collected in a standardized fashion (low risk of measurement bias). Our study thus avoided most pitfalls of historical cohorts.<sup>35</sup> In addition, patient treatment was not tailored according to RDW values which further decreased the risk of bias. As a consequence, the results here presented are likely to reflect the prognostic value of RDW in daily clinical practice. Second, the use of erythropoietin was not investigated, and much of the data regarding iron parameters, folate or vitamin B12, are lacking or absent (as in Paris cohort). These values could provide further insight into the variation in RDW as well as in results interpretation. Third, these cohorts do not overlap the same patient-population, since Paris cohort

subjects were likely to represent a less severe ADHF setting, as those were patients admitted to the general urgency, they did not necessarily have respiratory insufficiency, and had a much lower 180-day mortality rate. Nonetheless, Paris RDW results were also consistent with Porto results, suggesting that these findings can be generalizable to less severe ADHF populations. Fourth, we did not have discharge Hb in Paris cohort, hence hemoconcentration was not determined in this population. Fifth, discharge NP values could provide more accurate prognostic information; however, we used admission NPs in the net reclassification models due to the high percentage of missing discharge values. Last, the low number of patients in the 4 group categories reduces the precision of the estimated associations.

## CONCLUSION

As validated in 2 independent ADHF cohorts, an enlarging RDW during hospitalization for ADHF is associated with adverse outcomes. The prognostic value of elevated discharge RDW and rising RDW adds significant information (as assessed by net reclassification methods) on top of well-established prognostic variables (including hemoconcentration). These inexpensive and easily available biomarkers could help refine mid-term risk-stratification of patients admitted for ADHF.

## ACKNOWLEDGMENTS

*The authors thank Pierre Pothier for the editing of the manuscript.*

## REFERENCES

- Morris M, Davey F, Henry J. Clinical Diagnosis and Management by Laboratory Methods. Basic examination of blood. In 20th Edn. Philadelphia: WB Saunders Company; 2001.
- Forhecz Z, Gombos T, Borgulya G, et al. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. *Am Heart J*. 2009;158:659–666.
- Romero Artaza J, Carbia CD, Ceballo MF, et al. Red cell distribution width (RDW): its use in the characterization of microcytic and hypochromic anemias. *Medicina*. 1999;59:17–22.
- Pascual-Figal DA, Bonaque JC, Redondo B, et al. Red blood cell distribution width predicts long-term outcome regardless of anaemia status in acute heart failure patients. *Eur J Heart Fail*. 2009;840–846.
- Sangoi MB, Da Silva SH, da Silva JE, et al. Relation between red blood cell distribution width and mortality after acute myocardial infarction. *Int J Cardiol*. 2011;278–280.
- Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. *J Am Coll Cardiol*. 2007;40–47.
- Ani C, Ovbiagele B. Elevated red blood cell distribution width predicts mortality in persons with known stroke. *J Neurol Sci*. 2009;277:103–108.
- Hampole CV, Mehrotra AK, Thenappan T, et al. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. *Am J Cardiol*. 2009;104:868–872.
- Ye Z, Smith C, Kullo IJ. Usefulness of red cell distribution width to predict mortality in patients with peripheral artery disease. *Am J Cardiol*. 2011;107:1241–1245.
- Kim CH, Park JT, Kim EJ, et al. An increase in red blood cell distribution width from baseline predicts mortality in patients with severe sepsis or septic shock. *Crit Care*. 2013;17:R282.
- Bazick HS, Chang D, Mahadevappa K, et al. Red cell distribution width and all-cause mortality in critically ill patients. *Crit Care Med*. 2011;39:1913–1921.
- Boyle A, Sobotka PA. Redefining the therapeutic objective in decompensated heart failure: hemoconcentration as a surrogate for plasma refill rate. *J Card Fail*. 2006;12:247–249.
- Testani JM, Chen J, McCauley BD, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. *Circulation*. 2010;122:265–272.
- Davila C, Reyentovich A, Katz SD. Clinical correlates of hemoconcentration during hospitalization for acute decompensated heart failure. *J Card Fail*. 2011;17:1018–1022.
- van der Meer P, Postmus D, Ponikowski P, et al. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. *J Am Coll Cardiol*. 2013;61:1973–1981.
- Greene SJ, Gheorghiadu M, Vaduganathan M, et al. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Eur J Heart Fail*. 2013;15:1401–1411.
- Rossignol P, Masson S, Barlera S, et al. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. *Eur J Heart Fail*. 2015;17:424–433.
- Rossignol P, Menard J, Fay R, et al. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHEUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. *J Am Coll Cardiol*. 2011;58:1958–1966.
- McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2012;14:803–869.
- Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. *Eur J Heart Fail*. 2015;17:544–558.
- Zannad F, Garcia AA, Anker SD, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. *Eur J Heart Fail*. 2013;15:1082–1094.
- Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med*. 2008;27:157–172207–112.
- Uno H, Tian L, Cai T, et al. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. *Stat Med*. 2013;32:2430–2442.
- Adams KF Jr, Mehra MR, Oren RM, et al. Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure. *Am Heart J*. 2010;160:1142–1148.
- Ahmad T, O'Brien EC, Schulte PJ, et al. Evaluation of the incremental prognostic utility of increasingly complex testing in chronic heart failure. *Circ Heart Fail*. 2015;8:709–716.

26. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. *JAMA*. 2013;309:355–363.
27. O'Connor CM, Stough WG, Gallup DS, et al. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. *J Card Fail*. 2005;11:200–205.
28. Ferreira JP, Santos M, Almeida S, et al. Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors. *Clin Res Cardiol*. 2013;102:745–753.
29. Vaduganathan M, Greene SJ, Fonarow GC, et al. Hemoconcentration-guided diuresis in heart failure. *Am J Med*. 2014;127:1154–1159.
30. Testani JM, Brisco MA, Chen J, et al. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. *J Am Coll Cardiol*. 2013;62:516–524.
31. Fonarow GC, Adams KF Jr, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. *JAMA*. 2005;293:572–580.
32. O'Connor CM, Abraham WT, Albert NM, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *Am Heart J*. 2008;156:662–673.
33. Allen LA, Felker GM, Mehra MR, et al. Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. *J Card Fail*. 2010;16:230–238.
34. Aung N, Ling HZ, Cheng AS, et al. Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure. *Int J Cardiol*. 2013;168:1997–2002.
35. Rothman KJ, Greenland S. *Modern Epidemiology*. 2nd Edn. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.